Research at Bayer

As a research-based company, the Bayer Group firmly believes in innovation as a key driver for future growth. We have the necessary resources in place to realise further growth opportunities for the future through research and development activities. In 2007 we invested a total of EUR 2,578 million in research and development, compared with EUR 2,297 million in the previous year. It is particularly important for us to develop new products that strengthen our core businesses while at the same time continuously optimising our product portfolio and our manufacturing processes. Our research activities are closely aligned to the requirements of our markets, with customer needs and technological advances presenting opportunities for future innovation. With innovation projects in particular, our own research and development activities are supplemented by our international network of collaborations with leading universities, public-sector research institutes and partner companies. Through this pooling of expertise, we aim to rapidly translate new ideas into successful products.

Research in the three subgroups

Of the Group’s entire R&D expenditures, Bayer HealthCare accounted for 66 percent, Bayer CropScience for 25 percent and Bayer MaterialScience for 8 percent. Further information on each subgroup’s R&D activities is provided in Bayer HealthCare, Bayer CropScience and Bayer MaterialScience.

Triple-i

Triple-i is a global initiative to tap into our creative potential.

With more than 100,000 employees around the world overflowing with Inspiration, Ideas, and Innovation, it's obvious that many of these ideas could become new products. Triple-i provides the means of capturing these ideas and then building them into part of our business.

More than 3,000 ideas have been submitted since Triple-i launched.